

Frequent emergency department use and mortality in patients with substance and opioid use in Alberta: A population-based retrospective cohort study

Jessica Moe, MD, MSc, MA^{††}; Carlos A. Camargo Jr., MD, DrPH, MPH^{‡§}; Roger B. Davis, ScD[¶]; Susan Jelinski, PhD, DVM^{**††}; Brian H. Rowe, MD, MSc^{**††}

CLINICIAN'S CAPSULE

What is known about the topic?

Substance and opioid use are common among emergency department (ED) patients, and ED-based interventions are effective; however, optimal targeting is unclear.

What did this study ask?

Among ED patients with substance and opioid use, are frequent ED use and degree of frequent use associated with mortality?

What did this study find?

Frequent users with substance use and extremely frequent users with substance and opioid use had higher mortality than non-frequent users.

Why does this study matter to clinicians?

Clinicians should flag frequent users electronically and explore and address their unmet needs, because multiple visits are missed prevention opportunities.

use was defined by ≥ 5 visits in the previous year. Outcomes were unadjusted and adjusted (for age, sex, income) mortality within 90 days (primary), and 30 days, 365 days, and 2 years (secondary). To examine degree, frequent use was subcategorized into 5–10, 11–15, 16–20, and > 20 visits.

Results: Frequent users were older, lower income, and made lower acuity visits than non-frequent users. Frequent users with substance use had higher mortality at 365 days (hazard ratio [HR] 1.36 [1.04, 1.77]) and 2 years (HR 1.32 [1.04, 1.67]), but not at 90 or 30 days. Mortality did not differ for frequent users with opioid use overall. By degree, patients with substance use and > 20 visits/year and with opioid use and 16–20 visits/year demonstrated a higher 365-day and 2-year mortality.

Conclusions: Among patients with substance use, frequent ED use and extremely frequent use (> 20 visits/year) were associated with long-term but not short-term mortality. These findings suggest a role for targeted screening and preventive intervention.

ABSTRACT

Objectives: In the current opioid epidemic, identifying high-risk patients among those with substance and opioid use may prevent deaths. The objective of this study was to determine whether frequent emergency department (ED) use and degree of frequent use are associated with mortality among ED patients with substance and opioid use.

Methods: This cohort study used linked population-based ED (National Ambulatory Care Reporting System) and mortality data from Alberta. All adults ≥ 18 years with substance or opioid use-related visits based on diagnostic codes from April 1, 2012, to March 31, 2013, were included ($n = 16,389$). Frequent

RÉSUMÉ

Objectif: Dans le contexte actuel de l'épidémie de surdoses d'opioïdes, la détection des patients à risque élevé parmi ceux qui font usage d'opioïdes ou d'autres substances psychoactives peut avoir, pour effet, la prévention de la mort. L'étude visait donc à déterminer si les consultations fréquentes au service des urgences (SU) et le degré de fréquence étaient associés à la mortalité chez les patients faisant usage d'opioïdes ou d'autres substances psychoactives, traités au SU.

Méthode: Il s'agit d'une étude de cohortes fondée sur la population et reposant sur des bases de données liées en ce qui

From the *Vancouver General Hospital, Vancouver, BC; †Department of Emergency Medicine, University of British Columbia, Vancouver, BC; ‡Massachusetts General Hospital, Boston, MA; §Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA; ¶Department of Biostatistics, Harvard T.H. Chan School of Public Health, Harvard Medical School, Boston, MA; **Department of Emergency Medicine, University of Alberta, Edmonton, AB; ††Alberta Health Services, Edmonton, AB; and the ‡‡Emergency Strategic Clinical Network, Alberta Health Services, Edmonton, AB.

Correspondence to: Dr. Jessica Moe, Vancouver General Hospital Emergency Department, Jim Pattison Pavilion 920 West 10th Avenue, Vancouver, BC V5Z 1M9; Email: jessica.moe@gmail.com

concerne les consultations au SU (Système national d'information sur les soins ambulatoires) et la mortalité, en Alberta. Ont été inclus dans l'étude tous les adultes ≥ 18 ans ayant consulté pour des troubles liés à l'usage d'opioïdes ou d'autres substances psychoactives, d'après les codes de diagnostic inscrits du 1^{er} avril 2012 au 31 mars 2013 ($n = 16\ 389$). On entendait par « visites fréquentes » ≥ 5 consultations (cons.) au cours de l'année précédente. Les résultats recherchés consistaient en la mortalité brute et la mortalité rajustée selon l'âge, le sexe et les revenus au cours des 90 jours suivants (critère d'évaluation principal) ainsi qu'au bout de 30 jours, de 365 jours et de 2 ans (critères d'évaluation secondaires). Quant au degré de fréquence, le nombre de visites a été subdivisé en tranches de 5-10, 11-15, 16-20 et > 20 consultations.

Résultats: Les usagers fréquents étaient des personnes plus âgées, ayant des revenus plus faibles et consultant pour des troubles moins graves que les usagers non fréquents. Parmi les usagers fréquents, ceux qui utilisaient des substances psychoactives connaissaient une mortalité plus

élevée au bout de 365 jours (rapport des risques instantanés [RRI] : 1,36 [1,04–1,77]) et de 2 ans (RRI : 1,32 [1,04–1,67]), mais pas au bout de 90 jours ou de 30 jours. Par contre, il n'y avait pas de différence de mortalité chez les usagers fréquents utilisant des opioïdes, dans l'ensemble. Enfin, la mortalité calculée en fonction du degré de fréquence chez les patients faisant usage de substances psychoactives et comptant > 20 cons./année ainsi que chez ceux faisant usage d'opioïdes et comptant 16-20 cons./année était plus élevée au bout de 365 jours et de 2 ans.

Conclusion: Une fréquence élevée et extrêmement élevée de consultations (> 20 /année) au SU chez les patients faisant usage de substances psychoactives a été associée à la mortalité à long terme mais pas à court terme. Les résultats laissent donc croire à la pertinence d'un dépistage ciblé et d'interventions préventives.

Keywords: Emergency medicine, opioid-related disorders, public health, substance-related disorders

INTRODUCTION

Substance and opioid use are common among emergency department (ED) patients,^{1–3} especially among frequent ED users.^{4–7} In the current opioid epidemic, frequent ED presentation is increasingly being recognized as a harbinger of poor patient outcome; patients often make frequent ED visits prior to near-fatal overdose events.^{8,9} These ED visits are often missed opportunities to intervene. If frequent ED use could identify patients with substance and opioid use who are at risk of dying, a visit flagging system could enable practitioners to initiate ED-based brief interventions known to be effective, to engage patients with necessary follow-up care (e.g., addictions services), and ultimately to prevent mortality.^{10–12} Although frequent ED users have a higher mortality than non-frequent users in general,¹³ they are heterogeneous,^{6,14,15} and this risk has not been elaborated among patients with substance use. Additionally, frequent users likely differ by degree, that is, those at the extremes of frequent use (e.g., ≥ 16 visits/year) likely have different characteristics and outcomes than those with moderately high use (e.g., 5–15 visits/year). For instance, psychiatric comorbidities and non-urgent presentations are more common among patients with ≥ 18 annual visits; however, whether a “dose-response” relationship exists for mortality remains unclear.^{6,16} Despite important prevention implications, to date, no system-level study has evaluated whether

frequent ED use is associated with all-cause mortality in patients with substance and opioid use.

The objective was primarily to determine among ED patients with substance or opioid use whether frequent ED use in the previous 12 months was independently associated with mortality compared with non-frequent ED use, and, secondarily, whether mortality differed by degree of frequent use. We hypothesized that frequent use would be associated with mortality in ED patients presenting with substance or opioid use-related concerns.

METHODS

Study design and setting

This is a population-based, cohort study obtained from linked electronic ED visit and mortality databases evaluating patients who presented between April 1, 2012, and March 31, 2013. The study adheres to the RECORD reporting guidelines.¹⁷ The study setting is Alberta, Canada, with a population of over 4 million served by more than 100 EDs.

Data sources

The ED visit data were drawn from the National Ambulatory Care Reporting System administrative database

containing all provincial ED visits.¹⁸ This database contains patient demographic information (i.e., personal health number, age, sex, postal code) and ED visit information (i.e., arrival mode, visit date, visit time, Canadian Triage and Acuity Scale level [CTAS]¹⁹), in-ED care (i.e., provider details, procedures), and outcome (International Classification of Diseases and Related Health Problems-10 diagnostic codes, disposition date, time, and destination). The CTAS categorizes patient presentations based on severity. This ranges from resuscitation (Level 1) requiring immediate physician assessment, to non-urgent (Level 5) with a suggested time to physician within 2 hours.²⁰ Previous studies have validated the scale's ability to accurately predict patient outcomes and resource utilization, and have demonstrated high inter-rater reliability.^{20–22}

The Canadian Institute of Health Information performs annual quality checks on National Ambulatory Care Reporting System data to ensure its accuracy.²³ For the years of data analysed, incomplete ED record-level data were negligible (0.03% to 0.5%), and Albertan ED submissions met the most complete reporting standard (Level 3).^{24–26} Additionally, Alberta has independent validation processes for its electronic ambulatory care data.²⁷ Furthermore, external validation studies have found 98% agreement for encounter and demographic data and 87% agreement for diagnostic coding.²⁸

Mortality for all Alberta residents is captured within the Vital Statistics Registry, which records death date and demographic information.²⁹ Vital statistics data were collected until the final study date, December 31, 2014.

The final database for this study was created by linking the National Ambulatory Care Reporting System and vital statistics registries using postal code, birthdate, and sex. The data for this study were obtained by the Alberta Health Services Data Integration Management and Reporting Service.³⁰

Study population

The study included all adult patients (≥ 18 years old at time of index visit) who presented to an Albertan ED at least once during the study year (April 1, 2012, to March 31, 2013) for a substance use-related concern. Visits were classified as being related to substance use if an *a priori* group of diagnostic codes was listed as the primary or secondary diagnoses. Additional fields were excluded to limit misclassification from coding failure.

The primary definition consisted of ICD-10 codes within the category, “Mental and behavioural disorders due to psychoactive substance use” (F10–F19), based on a previously published algorithm.³¹ Two additional sensitivity analyses were conducted using alternative ICD-10 code-based substance use definitions: firstly, a more comprehensive definition including additional selected codes within the category, “Poisoning by drugs, medicaments and biological substances” (T36–T50), and, secondly, a definition including all F10–F19 codes except those pertaining to the use of tobacco (F17).

A separate analysis of opioid use-related ED visits was performed because we hypothesized that the analysis of 2012–2013 data may provide important insight into the growth of the current public health issue. These were defined as visits with a primary or secondary ICD-10 diagnosis within the category, “Mental and behavioural disorders due to use of opioids” (F11) or certain codes within the category, “Poisoning by narcotics and psychodysleptics” (T40), consistent with the definition used by Alberta Health Services.³²

In the entire database, 101 visits attributing to 14 unique patient identifiers had an index visit that occurred after the recorded death date. These visits were deleted as presumed erroneous entries; they represented 0.4% (101/24,880) of the study database.

Definition of frequent ED use

Patients were defined as frequent ED users if they had made ≥ 5 ED visits for any reason in the 12 months prior to the index visit (i.e., first visit within the study year). Non-frequent users had made ≤ 4 visits. The threshold of ≥ 5 visits corresponded to the 95th percentile of annual visits made by adult patients in Alberta, as suggested in previous studies.¹⁵ An additional sensitivity analysis defined frequent ED use based on the number of substance use-related visits (rather than visits for any reason).

To assess whether mortality risk differed by degree, the frequent use definition was subcategorized into four groups: 5–10, 11–15, 16–20, and > 20 visits. Patients within the categories 16–20 and > 20 visits/year were considered to have extremely frequent ED use.

Key outcome measures

The primary endpoint was survival at 90 days following the index visit. Secondary endpoints were survival at 30

days, 365 days, and 2 years. Deaths were recorded over the entire study period from the index visit until December 31, 2014.

Statistical methods

Unadjusted mortality for frequent and non-frequent users was assessed using log-rank tests. Adjusted mortality was assessed using multivariable Cox proportional hazards regression and is reported as hazard ratios (HRs).

Age, sex, and postal-code-derived income^{33–35} were included in the model as important potential confounders. Income was dichotomized as above or below the median income for the cohort. Missing income data ($n = 1032$) were included as a separate category. Additional sensitivity analyses were performed to account for missing data by excluding missing entries and excluding income entirely as a covariate. All analyses were performed using SAS 9.4 (SAS Institute Inc., Cary, NC) and used a two-tailed $p < 0.05$.

Power calculation

Estimating that our frequent user population comprised 20% of our total cohort, 298 mortality events were necessary to detect an HR of 1.5 for mortality among frequent users compared with non-frequent users, with 80% power and an $\alpha = 0.05$ two-tailed level of significance.

Ethical considerations

The study received ethics approval from the University of Alberta (Pro00058053_AME3), and administrative approval and a data sharing agreement from Alberta Health Services. Investigators accessed data after de-identification from a secure research server.

RESULTS

Characteristics of study subjects

Visit and patient characteristics

A total of 16,389 patients accounted for 24,880 substance use visits during the study year. Frequent users comprised 3,209 (19.6%) patients and 9,719 (39.1%) visits.

Within the study year, 1,787 patients made 2,241 visits for opioid use. Among patients with opioid use, 481 (26.9%) frequent users accounted for 821 (36.6%) visits.

Baseline patient and visit characteristics are presented in [Table 1](#). Among patients with substance and opioid use, frequent users were older, lower income, and more often resided rurally than non-frequent users. Furthermore, visits by frequent users were lower acuity (proportionally fewer triage level 1 or 2 visits) and were hospitalized less often.

Main results

Unadjusted mortality

[Table 2](#) reports unadjusted mortality estimates. Overall mortality was low in all groups, and 364 total mortality events (92 among frequent users and 272 among non-frequent users) were observed within the substance use cohort. Among substance use patients, no mortality difference was identified for frequent users compared with non-frequent users at 90 days or at 30 days. Mortality was higher for frequent users compared with non-frequent users at 365 days (2.3%, 95% confidence interval [CI]: 1.8, 2.8 versus 1.6%, 95% CI: 1.4, 1.8) and at 2 years (2.9%, 95% CI: 2.3, 3.4 versus 2.0%, 95% CI: 1.8, 2.3).

Among patients with opioid use, there was no significant difference between frequent users and non-frequent users for mortality at 90 days, 30 days, 365 days, or 2 years.

Adjusted mortality

[Table 3](#) presents the results of multivariable regression analyses. Frequent use was not significantly associated with 90-day mortality for patients with substance use; however, it was significantly associated with mortality at 365 days (HR 1.36 [95% CI: 1.04, 1.77]) and 2 years (HR 1.32 [95% CI: 1.04, 1.67]) when controlling for age, sex, and income. For patients with opioid use, frequent use was not associated with mortality at 90 days, 30 days, 365 days, or 2 years.

By degree (5–10, 11–15, 16–20, and > 20 visits), frequent use was significantly associated with mortality for patients with substance use and > 20 visits/year at 365 days (HR 1.88 [95% CI: 1.03, 3.44]) and at 2 years (HR 1.89 [95% CI: 1.10, 3.22]) ([Table 4](#)). Frequent use was significantly associated with mortality for patients with opioid use and 16–20 visits/year at 365 days (HR 3.62 [95% CI: 1.12, 11.66]) and at 2 years (HR 3.37

Table 1. Patient characteristics of frequent and non-frequent ED users among patients with substance and opioid use

	Frequent ED users with substance use	Non-frequent ED users with substance use	Total patients with substance use	Frequent ED users with opioid use	Non-frequent ED users with opioid use	Total patients with opioid use
Total patient number (N)	3,209	13,180	16,389	481	1,306	1,787
Age (mean, SD)	41 (14)	38 (15)	–	44 (15)	41 (17)	–
Male (n, %)	1,905 (59%)	8,610 (65%)	10,515 (64%)	208 (43%)	687 (53%)	895 (50%)
> Median income level (n, %)	1,310 (41%) Missing 250 (7.8%)	6,381 (48%) Missing 782 (5.9%)	7,691 (47%)	217 (45%) Missing 21 (4.4%)	653 (50%) Missing 57 (4.4%)	870 (49%)
Income (median, [Q1, Q3])	\$69,375 (\$61,063, \$76,374)	\$72,550 (\$61,150, \$83,039)	–	\$69,375 (\$61,063, \$76,374)	\$72,550 (\$61,063, \$83,039)	–
Rural status (n, %)	1,121 (38%)	2,576 (21%)	3,697 (23%)	143 (31%)	220 (18%)	363 (20%)

[95% CI: 1.05, 10.81]). These results remained consistent over the multiple sensitivity analyses.

DISCUSSION

Among ED patients with substance use identified from valid province-wide, population-based administrative data, frequent users were more likely to die at 365 days and at 2 years than non-frequent users, but not at 30 and 90 days, when controlling for age, sex, and income. Despite low overall mortality, these results support the hypothesis that frequent ED presentation is correlated with risk of dying among patients with substance use, generally, but not opioid use alone.

Our results suggest that frequent ED users with substance use are high-risk patients; this is likely related to specific complications (e.g., overdose, infections) but also probably reflects poor overall health, chronic illness, and low socioeconomic status.^{14,36,37} Urbanoski et al.⁴ (2018) found that frequent ED users with psychiatric conditions died more often if they had comorbid substance use. Our study expands on this finding by suggesting that, among all patients with substance use, frequent ED use is associated with long-term mortality. Our study furthermore builds on previous work that has correlated overdose with frequent ED presentation^{9,38} by suggesting that risk extends to all-cause mortality.

Our analysis provides a signal that mortality risk may differ by degree of frequent use (e.g., patients with ≥ 16 visits compared with those with 5–15 visits). Subcategorized by degree (5–10, 11–15, 16–20, and > 20 visits), higher mortality was only seen for extremely frequent users with substance use (> 20 visits) and opioid use (16–20 visits). This finding is unexpected given that previous studies have not demonstrated that extreme frequent users have higher mortality and, in fact, they make lower acuity visits.^{6,16} Our results support the importance of recognizing frequent users’ heterogeneity. Risk factors and outcomes should be explored within specific clinical subgroups. Additionally, our results suggest that recurrent low acuity visits should not distract from the long-term mortality risk among patients with substance use.

Our results also showed that frequent users with substance use made lower acuity visits and were admitted less often, which is somewhat paradoxical given their increased mortality risk. One possible explanation is that practitioner bias may enter into triage classifications.

Table 2. Visit characteristics of frequent and non-frequent ED users among patients with substance and opioid use

	ED visits by frequent users with substance use	ED visits by non-frequent users with substance use	Total ED visits for substance use	ED visits by frequent users with opioid use	ED visits by non-frequent users with opioid use	Total ED visits for opioid use
Total ED visit number (N)	9,719	15,161	24,880	821	1,420	2,241
Arrival by ambulance (n, %)	5,073 (52%)	6,959 (46%)	12,032 (48%)	320 (39%)	668 (47%)	998 (45%)
Visit LOS in minutes (median, Q1, Q3)	301 (137, 570)	312 (158, 560)	–	254 (121, 570)	311 (163, 592)	–
High acuity (CTAS 1 or 2) (n, %)	2,028 (21%) <i>Missing 258 (2.7%)</i>	4,791 (32%) <i>Missing 300 (2.0%)</i>	6,819 (27%)	232 (28%) <i>Missing 28 (3.4%)</i>	609 (43%) <i>Missing 31 (2.2%)</i>	841 (38%)
Admission to hospital (n, %)	1,190 (12%)	2,474 (16%)	3,664 (15%)	142 (17%)	309 (22%)	451 (20%)
Top five diagnoses (n, %)	F100 alcohol acute intoxication: 3,100 (32%) F101 alcohol harmful use: 1,260 (13%) F103 alcohol withdrawal state: 1,010 (10%) F102 alcohol dependence syndrome: 669 (7%) F191 multiple drug use and other psychoactive substances harmful use: 217 (2%)	F100 alcohol acute intoxication: 4,486 (30%) F101 alcohol harmful use: 1,589 (10%) F103 alcohol withdrawal state: 1,461 (10%) F102 alcohol dependence syndrome: 779 (5%) F191 multiple drug use and other psychoactive substances harmful use: 352 (2%)	–	F113 opioid withdrawal state: 198 (24%) T402 poisoning by narcotics and psychodysleptics [other opioids]: 120 (15%) F112 opioid dependence syndrome: 67 (8%) F111 opioid harmful use: 65 (8%) T406 poisoning by narcotics and psychodysleptics [other and unspecified narcotics]: 38 (5%)	F113 opioid withdrawal state: 304 (21%) T402 poisoning by narcotics and psychodysleptics [other opioids]: 298 (21%) F112 opioid dependence syndrome: 93 (7%) T406 poisoning by narcotics and psychodysleptics [other and unspecified narcotics]: 87 (6%) F111 opioid harmful use: 75 (5%)	–

LOS = length of stay

Table 3. Unadjusted mortality estimates for frequent and non-frequent ED users

Time frame	Mortality (95% CI)	
	Frequent ED users (≥ 5 visits)	Non-frequent ED users (≤ 4 visits)
Substance use		
90 Days (primary outcome)	0.7% (0.4%, 1.0%)	0.7% (0.5%, 0.8%)
30 Days	0.3% (0.1%, 0.5%)	0.3% (0.2%, 0.4%)
365 Days	2.3% (1.8%, 2.8%)*	1.6% (1.4%, 1.8%)
2 Years	2.9% (2.3%, 3.4%)*	2.0% (1.8%, 2.3%)
Opioid use		
90 Days (primary outcome)	1.5% (0.4%, 2.5%)	1.4% (0.8%, 2.1%)
30 Days	0.4% (0.0%, 1.0%)	1.0% (0.5%, 1.5%)
365 Days	4.8% (2.9%, 6.7%)	3.2% (2.3%, 4.2%)
2 Years	4.8% (2.9%, 6.7%)	3.5% (2.5%, 4.5%)

*Significant at $p < 0.05$

Another explanation is that medical complications of substance use (e.g., cellulitis, falls) are rapidly diagnosed and treated.³⁹ Finally, many of these patients would likely have medical and psychosocial needs (which may potentially be inadequately addressed by existing services) that would necessitate high healthcare service use overall, of which frequent ED utilization is one aspect.⁴⁰ Whatever the cause, it is possible that these multiple minor ED visits indicate ongoing high-risk behaviours that increased frequent users' overall long-term mortality. In retrospect, these minor events represent missed prevention opportunities and highlight the need for screening.

Limitations

This study has several limitations. Firstly, our diagnostic code-based definitions have not been validated. Nonetheless, they are aligned with current standards,^{31,32} and our results remained consistent in multiple sensitivity analyses exploring a range of definitions. Secondly, the algorithm used to link the National Ambulatory Care Reporting System and Vital Statistics databases was not validated. Nonetheless, it is expected to be robust due to the requirement of three matching pieces of demographic information. It did not achieve a perfect match; however, erroneous entries represented a very

small number of visits relative to the entire database (0.4%) and are unlikely to have affected results. Thirdly, there is a small possibility of losses to follow-up (e.g., patients not properly identified at death or who moved out of the province). Overall, censored data are likely minimal given the comprehensive provincial database and previously low documented rates of inter-provincial healthcare claims (approximately 2% for Alberta and Canada).⁴¹ Fourthly, our ability to control for potential confounders was limited by information available in the National Ambulatory Care Reporting System database. We were unable to adjust for comorbidities, end-of-life status or receipt of palliative/hospice care, patient complexity, homelessness or aboriginal status, which are not reliably recorded. Our inability to control for comorbidities in this analysis is a study limitation. In particular, it is possible that frequent ED use is associated with psychiatric comorbidities or chronic medical conditions, and that adequately controlling for these factors may help explain the difference in mortality observed between groups. Frequent ED presentations are, however, important considerations in their own right, because they are an easily measurable indicator that allows preventive intervention to be initiated; our study provides justification for more detailed analyses of potential underlying drivers of increased mortality among frequent ED users with substance use. Fifthly, our analysis is limited by missing data, particularly for income. In spite of this, our results remained consistent over multiple sensitivity analyses dealing with the missing income variable. Finally, despite the low overall mortality rates observed among all groups studied, given the importance of the outcome (mortality) and the public health crisis that exists, we argue that this small difference has the potential to have an important impact across Canada (assuming similar provincial event rates). This analysis of 2012–2013 data is an important precursor of what has likely become an increasingly significant issue in the context of the current burgeoning opioid epidemic and ongoing societal issues of alcohol and other substance-related disorders. Evidence shows that numbers of substance and opioid use-related ED visits continue to climb.⁴² Therefore, the small mortality difference that we detected at a population level likely translates to many individual lives at stake. Our results provide an important reference point and set the stage for current analyses by highlighting an important signal of risk among extremely frequent ED users presenting with substance and opioid use. This association likely

Table 4. Adjusted mortality estimates by degree of frequent ED use

ED visit number	Mortality hazard ratio (95% CI)			
	90-Day	30-Day	365-Day	2-Year
Substance use				
≥ 5 (Primary definition)	0.96 (0.60, 1.53)	0.75 (0.37, 1.54)	1.36 (1.04, 1.77)*	1.32 (1.04, 1.67)*
5–10	1.02 (0.60, 1.73)	0.88 (0.40, 1.94)	1.14 (0.83, 1.56)	1.06 (0.79, 1.42)
11–15	0.30 (0.04, 2.15)	0.0 (0.0,)	1.30 (0.71, 2.38)	1.49 (0.90, 2.46)
16–20	2.14 (0.68, 6.76)	1.39 (0.19, 10.08)	1.93 (0.91, 4.09)	1.72 (0.85, 3.46)
> 20	0.85 (0.21, 3.46)	0.86 (0.12, 6.24)	1.88 (1.03, 3.44)*	1.89 (1.10, 3.22)*
Opioid use				
≥ 5 (Primary definition)	0.92 (0.39, 2.20)	0.39 (0.09, 1.72)	1.43 (0.86, 2.38)	1.31 (0.79, 2.17)
5–10	1.06 (0.40, 2.82)	0.69 (0.16, 3.07)	1.29 (0.71, 2.34)	1.19 (0.66, 2.15)
11–15	0.0 (0.0,)	0.0 (0.0,)	0.29 (0.04, 2.07)	0.27 (0.04, 1.96)
16–20	3.37 (0.45, 25.22)	0.0 (0.0,)	3.62 (1.13, 11.66)*	3.37 (1.05, 10.81)*
> 20	1.09 (0.15, 8.08)	0.0 (0.0,)	2.20 (0.87, 5.52)	2.12 (0.85, 5.31)

*Significant at $p < 0.05$

has become stronger and merits repeat evaluation using data collected since 2012–2013.

CONCLUSIONS

This study suggests that, among patients with substance use, generally, but not opioid use alone, frequent ED use is associated with a higher risk for long-term (365-day and 2-year) but not short-term (90- and 30-day) mortality compared with non-frequent ED users. Our analysis appears to signal that extremely frequent ED use is associated with mortality among patients with substance use (> 20 visits) and opioid use (16–20 visits). This finding may be generalizable across Canada; for instance, in British Columbia, at the epicentre of the current opioid epidemic, similar evidence is emerging.⁸ Extremely frequent users might benefit from targeted prevention, such as by flagging them using existing electronic visit tracking systems already operational in many EDs. Additionally, educating clinicians about exploring patient needs and reasons for frequent presentation will facilitate identification of appropriate interventions. Future research should link ED data to additional databases to better adjust for patient complexity and should assess the effectiveness of targeted interventions for frequent ED users with substance and opioid use.

Supplementary material: The supplementary material for this article can be found at <https://doi.org/10.1017/cem.2019.15>.

Acknowledgements: The authors acknowledge the support of the Emergency Strategic Clinical Network of Alberta Health Services (AHS) for access to the health data.

Financial support: Author JM's research is currently supported by the University of British Columbia Department of Emergency Medicine and the Vancouver Acute Emergency Physicians' Association. At the time of the study, author BHR's research was supported by a Tier I Canada Research Chair in Evidence-based Emergency Medicine funded by the Canadian Institutes of Health Research (CIHR) through the Government of Canada. He is currently supported by the CIHR as the Scientific Director of the Institute of Circulatory and Respiratory Health (ICRH). At the time of the study, author SJ's research was supported by the Emergency Strategic Clinical Network of AHS. The funders take no responsibility for the content or interpretation of these data.

Presentations: A related abstract was presented as a poster presentation at the Canadian Association of Emergency Physicians Conference in May 2018.

REFERENCES

- Sanjuan PM, Rice SL, Witkiewitz K, *et al.* Alcohol, tobacco, and drug use among emergency department patients. *Drug Alcohol Depend* 2014;138:32–8.
- Cederbaum JA, Guerrero EG, Mitchell KR, Kim T. Utilization of emergency and hospital services among individuals in substance abuse treatment. *Subst Abuse Treat Prev Policy* 2014;9(16).
- Wu L, Swartz MS, Wu Z, *et al.* Alcohol and drug use disorders among adults in emergency department settings in the United States. *Ann Emerg Med* 2012;60(2):180.e5.
- Urbanoski K, Cheng J, Rehm J, Kurdyak P. Frequent use of emergency departments for mental and substance use disorders. *Emerg Med J* 2018;35:220–5.

5. Liu SW, Nagurney JT, Chang Y, *et al.* Frequent ED users: are most visits for mental health, alcohol, and drug-related complaints? *Am J Emerg Med* 2013;31:1512–5.
6. Doupe MB, Palatnick W, Day S, *et al.* Frequent users of emergency departments: developing standard definitions and defining prominent risk factors. *Ann Emerg Med* 2012;60(1):24.
7. Curran GM, Sullivan G, Williams K, *et al.* The association of psychiatric comorbidity and use of the emergency department among persons with substance use disorders: an observational cohort study. *BMC Emerg Med* 2008;8(1):17.
8. Otterstatter M. Analyzing patterns of health care utilization among people who overdose from illegal drugs in British Columbia. BC Centre for Disease Control, Vancouver, BC, March 7, 2018.
9. Hasegawa K, Brown DFM, Tsugawa Y, Camargo CA. Epidemiology of emergency department visits for opioid overdose: a population-based study. *Mayo Clin Proceed* 2014;89(4):462–71.
10. Crawford MJ, Patton R, Touquet R, *et al.* Screening and referral for brief intervention of alcohol-misusing patients in an emergency department: a pragmatic randomised controlled trial. *Lancet* 2004;364(9442):1334–9.
11. Cunningham RM, Bernstein SL, Walton M, *et al.* Alcohol, tobacco, and other drugs: future directions for screening and intervention in the emergency department. *Acad Emerg Med* 2009;16(11):1078–88.
12. D’Onofrio G, Degutis LC. Preventive care in the emergency department: screening and brief intervention for alcohol problems in the emergency department: a systematic review. *Acad Emerg Med* 2002;9(6):627–38.
13. Moe J, Kirkland S, Ospina MB, *et al.* Mortality, admission rates and outpatient use among frequent users of emergency departments: a systematic review. *Emerg Med J* 2016;33(3):230–6.
14. LaCalle E, Rabin E. Frequent users of emergency departments: the myths, the data, and the policy implications. *Ann Emerg Med* 2010;56(1):42–8.
15. Moe J, Bailey AL, Oland R, *et al.* Defining, quantifying, and characterizing adult frequent users of a suburban Canadian emergency department. *CJEM* 2013;15(4):214–26.
16. Ruger JP, Richter CJ, Spitznagel EL, Lewis LM. Analysis of costs, length of stay, and utilization of emergency department services by frequent users: implications for health policy. *Acad Emerg Med* 2004;11(12):1311–7.
17. Benchimol EI, Smeeth L, Guttman A, *et al.* The REporting of studies conducted using observational routinely-collected health data (RECORD) statement. *PLoS Med* 2015;12(10).
18. Canadian Institute for Health Information. National ambulatory care reporting system metadata (NACRS); 2017. Available at: <https://www.cih.ca/en/national-ambulatory-care-reporting-system-metadata> (accessed July 13, 2017).
19. Canadian Association of Emergency Physicians. The Canadian Triage and Acuity Scale: Combined Adult/Paediatric Educational Program, Version 2.5b; 2013, November. Available at: http://ctas-phctas.ca/wp-content/uploads/2018/05/participant_manual_v2.5b_november_2013_0.pdf (accessed July 13, 2017).
20. Lee JY, Oh SH, Peck EH, *et al.* The validity of the Canadian triage and acuity scale in predicting resource utilization and the need for immediate life-saving interventions in elderly emergency department patients. *Scand J Trauma Resusc Emerg Med* 2011;19(68).
21. Dong SL, Bullard MJ, Meurer DP, *et al.* Predictive validity of a computerized emergency triage tool. *Acad Emerg Med* 2007;14(1):16–21.
22. Beveridge R, Ducharme J, Janes L, *et al.* Reliability of the Canadian emergency department triage and acuity scale: interrater agreement. *Ann Emerg Med* 1999;34(2):155–9.
23. Canadian Institute for Health Information. Data quality documentation, national ambulatory care reporting system – multi-year information. Ottawa, ON: Canadian Institute for Health Information; 2012.
24. Canadian Institute for Health Information. Data quality documentation, National Ambulatory Care Reporting System – current-year information, 2011–2012. Ottawa, ON: Canadian Institute for Health Information; 2012.
25. Canadian Institute for Health Information. Data quality documentation, National Ambulatory Care Reporting System – current-year information, 2012–2013. Ottawa, ON: Canadian Institute for Health Information; 2013.
26. Canadian Institute for Health Information. Data quality documentation, National Ambulatory Care Reporting System – current-year information, 2013–2014. Ottawa, ON: Canadian Institute for Health Information; 2014.
27. Health Information Standards Committee for Alberta. National Ambulatory Care Reporting System and comprehensive ambulatory care classification system data set. Edmonton, AB: Government of Alberta; March 20, 2012.
28. Alberta Health and Wellness. Alberta health and wellness ambulatory care re-abstraction study: executive report. Edmonton, AB; June 30, 2006. Available at: <https://open.alberta.ca/dataset/8cdd925a-8a15-4e81-bfd7-91aeff6470f8/resource/a74af261-80a4-4707-91f3-3631a8ee8ad9/download/ac-reabstraction-report-2006.pdf> (accessed June 25, 2017).
29. Government of Alberta. Death certificates and documents. Available at: <https://www.alberta.ca/order-death-certificate.aspx> (accessed July 20, 2017).
30. Alberta Health Services. Analytics, data integration, measurement and reporting. Calgary, AB; 2017. Available at: <https://www.albertahealthservices.ca/findhealth/service.aspx?Id=1661&facilityId=1005258> (accessed July 13, 2017).
31. Ontario Ministry of Health and Long-Term Care. Repeat emergency visits for substance abuse. Toronto, ON. October 19, 2015.
32. Alberta Health. Opioids and substances of misuse Alberta report: Alberta report, 2016 Q4. Alberta Health, Alberta; February 7, 2017.
33. Statistics Canada. Postal code conversion file plus (PCCF+) version 6B, reference guide: November 2014 postal codes; 2015.
34. Statistics Canada. Census profile – 2016 census. Statistics Canada catalogue no. 98-316-X2016001. Statistics Canada; 2017. Available at: <https://www12.statcan.gc.ca/census-recensement/2016/dp-pd/prof/index.cfm?Lang=E> (accessed July 13, 2017).
35. Thomas AJ, Eberly LE, Davey Smith G, Neaton JD. ZIP-code-based versus tract-based income measures as long-term risk-adjusted mortality predictors. *Am J Epidemiol* 2006;164(6):586–90.
36. Sun BC, Burstin HR, Brennan TA. Predictors and outcomes of frequent emergency department users. *Acad Emerg Med* 2003;10(4):320–8.

37. Khan Y, Glazier RH, Moineddin R, Schull MJ. A population-based study of the association between socioeconomic status and emergency department utilization in Ontario, Canada. *Acad Emerg Med* 2011;18(8):836–43.
38. Brady JE, DiMaggio CJ, Keyes KM, *et al.* Emergency department utilization and subsequent prescription drug overdose death. *Ann Epidemiol* 2015;25(8):619.e2.
39. Kerr T, Wood E, Grafstein E, *et al.* High rates of primary care and emergency department use among injection drug users in Vancouver. *J Public Health* 2004;27(1):62–6.
40. Byrne M, Murphy AW, Plunkett PK, *et al.* Frequent attenders to an emergency department: a study of primary health care use, medical profile, and psychosocial characteristics. *Ann Emerg Med* 2003;41(3):309–18.
41. Canadian Institute for Health Information. Have health card, will travel: out-of-province/-territory patients. Ottawa, ON: Canadian Institute for Health Information; 2010.
42. Canadian Institute for Health Information, Canadian Centre on Substance Abuse. Hospitalizations and emergency department visits due to opioid poisoning in Canada. Ottawa, ON: Canadian Institute for Health Information; 2016.